OUR UNDERSTANDING OF THE PHENOTYPE of obstructive sleep apnea has expanded rapidly over the past several decades. Once thought to be simply a source of sleepiness, sleep apnea is now established as an independent risk factor for significant cardiovascular disease, including systemic hypertension, myocardial ischemia and infarction, stroke, and congestive heart failure (11) . Obstructive sleep apnea may also impair insulin sensitivity and adversely affect glucose control (7) . At the same time, the central nervous system effects of sleep apnea extend beyond sleepiness to refractory sleepiness and cognitive impairments, including executive function, memory, and, potentially, peripheral nerve impairment (2, 6) . A major clinical question, then, is whether a common mechanism of injury underlies such diverse morbidities. In this issue of the Journal of Applied Physiology, Sharma and colleagues (9a) used an animal model of sleep apnea oxygenation patterns to identify an important posttranslational modification that may contribute to some of the significant morbidities of obstructive sleep apnea.
The basic pathophysiology of obstructive sleep apnea involves an elaborate orchestration of many physiological perturbances. Central to the disorder, individuals with obstructive sleep apnea have a propensity toward collapse of the upper airway (10) . During wakefulness increased activity of the upper airway dilator muscles maintains airway patency. A normal aspect of sleep is reduced muscle tone, which in individuals with sleep apnea results in pharyngeal collapse (8) . With collapse, ventilation is impaired, raising CO 2 and lowering O 2 levels. At the same time, increased pump muscle effort against a closed pharynx reduces preload and causes significant afterload on the heart. Hypoxemia increases sympathetic activity. Sensory stimulation from the strained pharyngeal tissues, increased effort, and hypercapnia leads to arousal and sudden pharyngeal patency (8) . The arousal results in an even larger sympathetic surge and resumption of a patent airway, which, in turn, increase preload and improve afterload. This sympathetic surge, coupled with the hemodynamic changes, results in increased cardiac output and blood pressure (11) . On return to the sleep state, this entire pattern of physiological perturbances repeats itself, over and over again.
Although several of these physiological disturbances likely contribute to the associated morbidities of sleep apnea, it is quite evident that fluctuations in oxygenation explain, in large part, many of the pathophysiologies of sleep apnea. Animal models have been instrumental in determining that long-term exposure to intermittent hypoxia modeling sleep apnea oxygenation can cause hypertension, endothelial damage, and proinflammatory changes involved in cardiovascular morbidities and can increase insulin resistance and impair neurobehavioral functions, including learning and memory and wakefulness (3). Thus oxygenation fluctuations contribute significantly to morbidities, but through what molecular mechanisms?
Intermittent hypoxemia in animal models induces diverse transcriptional and translational and posttranslational changes through oxidative stress and other perturbations, but specific molecular modifications that might contribute to multiple pathophysiological changes have remained elusive (3). Sharma et al. (9a) have identified a potential mechanism by which intermittent hypoxia, as in sleep apnea, can activate a large number of peptides. These peptides have diverse physiological effects on blood pressure, appetite, metabolic control, behavioral state, and stress responses. ␣-Amidation is a rate-limiting terminal step in the activation of this group of peptides with diverse biological functions ( Table 1 ). The bifunctional enzyme peptidylglycine ␣-amidating monooxygenase acts in a two-step process to ␣-amidate and glyoxylate each of these peptides, resulting in their activation (5). Sharma et al. found that intermittent hypoxia activates the amidation component of this enzyme and activates at least two of the target peptides in the brain stem. The full list of ␣-amidated peptides is of great interest in sleep apnea, where various combinations of activations could lead to push-me, pull-you effects on cerebrovascular flow, peripheral vascular resistance, myocardial contractility, appetite and weight gain, sleep/wake activity, and glucose regulation, inasmuch as each peptide's effect in this group could be countered by another in the list. On further investigation, however, Sharma et al. identified a mechanism by which the push-me effects of one peptide may not be countered by another. They demonstrate effectively that activation of the ␣-amidating monooxygenase requires an increase in reactive oxygen species. Thus cells with greater reducing power and faster, more effective antioxidant responses will have less ␣-amidating monooxygenase activity, so their ␣-amidated peptides may not become activated. In contrast, cells that are more There is clinical support for an increase in neuropeptide Y (NPY), but not substance P (SP), in obstructive sleep apnea. Specifically, peripheral NPY is increased in subjects with sleep apnea (1) . Moderate increases in NPY in catecholaminergic cells peripherally and centrally have been shown to increase appetite, weight gain, insulin resistance, and triglyceride deposition in the liver (9) . SP is expected to counter the vasoconstrictive effects of NPY; however, SP levels appear to be lower in individuals with obstructive sleep apnea (12) . This finding suggests that not all ␣-amidated peptides will be activated to balance or counter each other's effects and demonstrates that push me without pull you can contribute to diverse pathophysiologies. Catecholaminergic neurons are particularly sensitive to oxidative stress and intermittent hypoxia (4); thus NPY may be "overrepresented" as an intermittent hypoxia-activated ␣-amidated peptide.
What is needed now to advance these important findings? Translational investigations that test endogenous peptide influences using careful dose-response studies of specific antagonists in mice exposed to intermittent hypoxia would help demonstrate endogenous activities of various peptides on physiological effects of intermittent hypoxia. These studies complemented with studies of transgenic mice with altered levels of a specific ␣-amidated peptide would help determine the roles of various neuropeptides in intermittent hypoxia hypertension, weight gain with longer term exposure, and insulin resistance. This information could lead to novel effective therapies for diverse morbidities in the highly prevalent disorder sleep apnea, so the pull-me effects can match the push-you effects.
